This company has been marked as potentially delisted and may not be actively trading. NASDAQ:ADAP Adaptimmune Therapeutics (ADAP) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Adaptimmune Therapeutics Stock (NASDAQ:ADAP) Get ADAP alerts:Sign Up Key Stats Today's Range$0.05▼$0.0750-Day Range$0.05▼$0.2252-Week Range$0.04▼$0.36Volume49.26 million shsAverage Volume57.14 million shsMarket Capitalization$15.35 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Adaptimmune Therapeutics plc is a clinical-stage biotechnology company focused on the development of novel T-cell therapies for the treatment of solid tumors. The company’s proprietary technology platform, known as SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cells, uses affinity-enhanced T-cell receptors (TCRs) to target cancer-associated antigens with precision. Adaptimmune’s research and development efforts are centered on engineering patient-derived T cells to recognize and eliminate tumor cells while sparing healthy tissues. Since its founding in 2008 as a spin-out from Oxford University, Adaptimmune has advanced multiple product candidates into clinical trials. Lead programs include ADP-A2M4, targeting the cancer testis antigen MAGE-A4, and ADP-A2AFP, directed against alpha-fetoprotein in liver cancer. The company also maintains preclinical discovery efforts against other tumor-associated antigens, aiming to expand its pipeline across a range of solid tumor indications such as ovarian, head and neck, and lung cancers. Adaptimmune operates research and development facilities in Oxford, U.K., and a clinical and manufacturing center in Philadelphia, Pennsylvania. The company conducts multicenter clinical trials primarily in the United States and Europe, collaborating with academic institutions and biopharmaceutical partners to facilitate patient access and advance its programs through late-stage development. Governed by a management team with deep expertise in oncology and cell therapy, Adaptimmune is led by Chief Executive Officer James Noble, who joined the company in 2021. Adaptimmune Therapeutics is publicly traded on the Nasdaq Global Market under the ticker symbol ADAP and continues to pursue strategic collaborations and potential regulatory filings as it works to bring its engineered T-cell therapies to patients with unmet medical needs.AI Generated. May Contain Errors. Read More Receive ADAP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Adaptimmune Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ADAP Stock News HeadlinesAdaptimmune Therapeutics PLC ADR ADAPYAugust 26, 2026 | morningstar.comMAdaptimmune Therapeutics PLC: Adaptimmune Reports Q1 Financial Results and Provides Business UpdateMay 22, 2026 | finanznachrichten.deElon Musk’s Hushed FCC Filing. Dec 8th.Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the largest markets in the world. James Altucher, who previously flagged Nvidia in 2008 and Bitcoin in 2013, says the filing could rival Tesla, SpaceX and xAI combined. Few investors know this filing exists, but that is expected to change quickly. | Paradigm Press (Ad)Sixteen new option listings and one option delisting on October 28thOctober 28, 2025 | msn.comAdaptimmune delists from Nasdaq, shifts focus after asset sale to US WorldMedsOctober 28, 2025 | bizjournals.comEvaxion Biotech appoints Tayton-Martin as new CEOOctober 27, 2025 | msn.comLiposarcoma Market Set to Grow at a Steady CAGR by 2034 Amid Increasing Clinical Research Activities | DelveInsightOctober 21, 2025 | finance.yahoo.comAdaptimmune stock plunges after announcing Nasdaq delisting plansOctober 20, 2025 | au.investing.comSee More Headlines ADAP Stock Analysis - Frequently Asked Questions How were Adaptimmune Therapeutics' earnings last quarter? Adaptimmune Therapeutics PLC (NASDAQ:ADAP) announced its earnings results on Wednesday, August, 13th. The biotechnology company reported ($0.11) earnings per share for the quarter, beating analysts' consensus estimates of ($0.15) by $0.04. The biotechnology company had revenue of $13.68 million for the quarter, compared to analyst estimates of $11.04 million. Adaptimmune Therapeutics had a negative net margin of 260.82% and a negative trailing twelve-month return on equity of 163.73%. When did Adaptimmune Therapeutics IPO? Adaptimmune Therapeutics (ADAP) raised $150 million in an initial public offering (IPO) on Wednesday, May 6th 2015. The company issued 9,400,000 shares at a price of $15.00-$17.00 per share. BofA Merrill Lynch, Cowen and Company and Leerink Partners served as the underwriters for the IPO and Guggenheim Securities was co-manager. What other stocks do shareholders of Adaptimmune Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Adaptimmune Therapeutics investors own include NVIDIA (NVDA), Agenus (AGEN), Verastem (VSTM), Sangamo Therapeutics (SGMO), BioCryst Pharmaceuticals (BCRX), Editas Medicine (EDIT) and AT&T (T). Company Calendar Last Earnings8/13/2025Today10/24/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ADAP CIK1621227 Webwww.adaptimmune.com Phone441235430000Fax44-12-3543-0001Employees490Year Founded2008Profitability EPS (Trailing Twelve Months)($0.65) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$70.81 million Net Margins-260.82% Pretax Margin-255.12% Return on Equity-163.73% Return on Assets-75.83% Debt Debt-to-Equity RatioN/A Current Ratio1.52 Quick Ratio1.29 Sales & Book Value Annual Sales$178.03 million Price / Sales0.09 Cash FlowN/A Price / Cash FlowN/A Book Value$0.05 per share Price / Book1.16Miscellaneous Outstanding Shares265,050,000Free Float232,080,000Market Cap$15.35 million OptionableOptionable Beta2.49 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:ADAP) was last updated on 10/27/2025 by MarketBeat.com Staff. From Our PartnersThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | Sponsored$0. Later: $29.97.Bill Poulos is giving away his Simple Options Trading For Beginners book through a temporary link. Once that l...Profits Run | SponsoredThe $100 Stock Behind Elon's Next MoveA small, publicly traded supplier trading under $100 a share has reportedly worked alongside Elon Musk for mor...Paradigm Press | SponsoredEarth's biggest energy source: near Grand CanyonThe largest energy source on Earth contains 50,000 times every oil and gas reserve on the planet combined - an...Behind the Markets | SponsoredHe turned $12K into $1.65M without touching Apple or TeslaTim Sykes turned $12,415 in gift money into more than $1.65 million before graduating college, without trading...Tim Sykes | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adaptimmune Therapeutics PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Adaptimmune Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
